Condition: Diabetes Mellitus, Type 2 · Cardiovascular Diseases · Diabetic Nephropathy Type 2 · Sponsor: Optithera
The goal of this pragmatic trial is to provide Real World Evidence (RWE) on the impact of the result of a polygenic risk prediction test of cardiorenal complications of T2D, so that more patients at high risk of these complications achieve over an 18 months period, recommended therapeutic targets. This will be demonstrated as a significant improvement in a composite value including HbA1c or systolic blood pressure (SBP) or albuminuria (UACR), or glomerular filtration rate (GFR) lowering. Researchers will compare the recommended therapeutic targets of uninformed and informed patients to see if the knowledge of the risk by the patients and their treating physicians improves achievement of these targets. Participants will: Have a saliva sampling to determine the genetic risk. Visit the clinic once every 3 months for checkups and tests Answer two questionnaires on quality of life.
This description comes directly from the study's public registry record.
Marie-Renée Guertin, il,cra · 514-249-4209 · marie-renee.guertin.chum@ssss.gouv.qc.ca
Johanne Tremblay, PhD · 514-890-8247 · johanne@optithera.onmicrosoft.com
Always discuss trial participation with your own doctor first.
| CHUM | Montreal, Quebec, Canada | Recruiting |
| ELNA Medical | Montreal, Quebec, Canada | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06586203